Prospective randomized clinical trial assessing the efficacy of denamarin for prevention of CCNU-induced hepatopathy in tumor-bearing dogs

Journal of Veterinary Internal Medicine

Volumn 25, Issue 4, 2011, Pages 838-845

  Skorupski, K A ^a   Hammond, G M ^a,c   Irish, A M ^a,d   Kent, M S ^a   Guerrero, T A ^a   Rodriguez, C O ^a   Griffin, D W ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NUTRAMAX LABORATORIES INC   (United States)

^c VCA Shoreline Veterinary Referral Emergency Center   (United States)

^d Veterinary Referral Associates   (United States)

Author keywords

Lomustine; S adenosylmethionine; Silybin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; LOMUSTINE; S ADENOSYLMETHIONINE; SILIBININ; SILYMARIN;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOG DISEASE; FEMALE; MALE; NEOPLASM; NONPARAMETRIC TEST; PATHOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TOXIC HEPATITIS;

ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; CHOLESTEROL; DOG DISEASES; DOGS; DRUG-INDUCED LIVER INJURY; FEMALE; LOMUSTINE; MALE; NEOPLASMS; PROSPECTIVE STUDIES; S-ADENOSYLMETHIONINE; SILYMARIN; STATISTICS, NONPARAMETRIC;

ANIMALIA; CANIS FAMILIARIS;

EID: 79960556328     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2011.0743.x     Document Type: Article

References (32)

1. Moore AS, London CA, Wood CA, et al. Lomustine (CCNU) for the treatment of resistant lymphoma in dogs. J Vet Intern Med 1999;13:395-398.
2. Williams LE, Rassnick KM, Power HT, et al. CCNU in the treatment of canine epitheliotropic lymphoma. J Vet Intern Med 2006;20:136-143.
3. Risbon RE, de Lorimier LP, Skorupski K, et al. Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU): A retrospective study of 46 cases (1999-2004). J Vet Intern Med 2006;20:1389-1397.
4. Rassnick KM, Moore AS, Williams LE, et al. Treatment of canine mast cell tumors with CCNU (lomustine). J Vet Intern Med 1999;13:6010-6015.
5. Skorupski KA, Clifford CA, Paoloni MC, et al. CCNU for the treatment of dogs with histiocytic sarcoma. J Vet Intern Med 2007;21:121-126.
6. Viotte G, Lahouel M, Ducastelle T, et al. Hepatotoxicity of (chloro-2-ethyl)-1-cyclohexyl-3-nitroso-1-urea (CCNU) in the rat. Pathol Biol (Paris) 1986;34:40-47.
7. Ahmed AE, Grissom M, el-Azhary R, et al. Studies on the mechanism of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU)-induced hepatotoxicity II. Biochemical and morphological characterization of the injury and its prevention by Phenobarbital. Cancer Chemother Pharmacol 1987;19:103-108.
8. Kretschmer NW, Boor PJ, el-Azhary RA, et al. Studies on the mechanism of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU)- induced hepatotoxicity III. Ultrastructural characterization of bile duct injury. Cancer Chemother Pharmacol 1987;19:109-117.
9. Henry MC, Davis RD, Schein PS. Hepatotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in dogs: The use of serial percutaneous liver biopsies. Toxicol Appl Pharmacol 1973;25:410-417.
10. Hosoya K, Lord LK, Lara-Garcia A, et al. Prevalence of elevated alanine transaminase activity in dogs treated with CCNU (lomustine). Vet Comp Oncol 2009;7:244-255.
11. Kristal O, Rassnick KM, Gliatto JM, et al. Hepatotoxicity associated with CCNU (lomustine) chemotherapy in dogs. J Vet Intern Med 2004;18:75-80.
12. Khan S, Ramwani JJ, O'Brien PJ. Hepatocyte toxicity of mechlorethamine and other alkylating anticancer drugs. Role of lipid peroxidation. Biochem Pharmacol 1992;43:1963-1967.
13. Ducastelle T, Raguenez-Viotte G, Fouin-Fortunet H, et al. The hepatotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in rats. Ultrastructural evidence of a delayed microtubular toxicity. Cancer Chemother Pharmacol 1988;22:153-162.
14. Friedel HA, Goa KL, Benfield P. S-adenosyl-l methionine: A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs 1989;38:389-416.
15. Stramentinoli G. Pharmacologic aspects of S-adenosylmethionine. Pharmacokinetics and pharmacodynamics. Am J Med 1987;83:35-42.
16. Center SA, Warner KL, Erb HN. Liver glutathione concentrations in dogs and cats with naturally occurring liver disease. Am J Vet Res 2002;63:1187-1197.
17. Cederbaum AI. Hepatoprotective effects of S-adenosyl-l-methionine against alcohol- and cytochrome P450 2E1-induced liver injury. World J Gastroenterol 2010;16:1366-1376.
18. Webster CR, Cooper J. Therapeutic use of cytoprotective agents in canine and feline hepatobiliary disease. Vet Clin North Am Small Anim Pract 2009;39:631-652.
19. Wellington K, Jarvis B. Silymarin: A review of its clinical properties in the management of hepatic disorders. BioDrugs 2001;15:465-489.
20. Fraschini F, Demartini G, Esposti D. Pharmacology of silymarin. Clin Drug Investig 2002;22:51-65.
21. Salmi HA, Sarna S. Effect of silymarin on chemical, functional, and morphological alterations of the liver. Scand J Gastroenterol 1981;17:517-521.
22. Kidd P, Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome: A silybin-phosphatidylcholine complex (Siliphos®). Altern Med Rev 2005;10:193-203.
23. Comelli MC, Mengs U, Schneider C, Prosdocimi M. Toward the definition of the mechanism of action of silymarin: Activities related to cellular protection from toxic damage induced by chemotherapy. Integr Cancer Ther 2007;6:120-129.
24. Vogel G, Tuchweber B, Trost W, Mengs U. Protection by silibinin against Amanita phalloides intoxication in Beagles. Toxicol Appl Pharmacol 1984;73:355-362.
25. Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989;9:105-113.
26. Center SA, Warner KL, McCabe J, et al. Evaluation of the influence of S-adenosylmethionine on systemic and hepatic effects of prednisolone in dogs. Am J Vet Res 2005;66:330-341.
27. Filburn CR, Kettenacker R, Griffin DW. Bioavailability of a silybin-phosphatidylcholine complex in dogs. J Vet Pharmacol Therap 2007;30:132-138.
28. Santini D, Vincenzi B, Massacesi C, et al. S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury. Anticancer Res 2003;23:5173-5179.
29. Ladas EJ, Kroll DJ, Oberlies NH, et al. A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL). Cancer 2010;116:506-513.
30. Vail DM. Veterinary Co-operative Oncology Group-Common toxicity criteria for adverse events (VCOG-CTCAE) following chemotherapy or biologic antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:194-213.
31. El-Sayed el-SM, Abdel-Aziz AA, Helal GK, et al. Protective effect of N-acetylcysteine against carmustine-induced myelotoxicity in rats. Food Chem Toxicol 2010;48:1576-1580.
32. Webster GJ, Kurtovic J, Singh-Grewal I, et al. Letter to the editor: Prevention of hepatotoxicity but loss of antimelanoma effect with combined fotemustine and anti-oxidant treatment. Int Med J 2004;34:298-299.